GLP-1 & weight loss · Evidence comparison
Semaglutide vs Retatrutide
Ozempic/Wegovy's semaglutide versus the investigational triple-agonist the weight-loss world is watching.
Semaglutide
Retatrutide
Headline claim shown. Grades are claim-specific — see the full breakdown below.
The evidence, side by side
Every graded claim from each brief. Grades are read straight from the source-checked briefs — one molecule can be strong for one use and weak for another.
Metabolic / weight loss
Semaglutide
Evidence grades
Metabolic / weight loss
Retatrutide
Evidence grades
Regulatory status at a glance
Semaglutide
FDA-approved prescription drug — the only fully approved compound on this site so far. Approved as Ozempic (injection, type 2 diabetes, 2017), Rybelsus (oral, type 2 diabetes, 2019), and Wegovy (injection, chronic weight management, 2021); Wegovy gained a cardiovascular-risk-reduction indication in March 2024, and an oral Wegovy (semaglutide 25 mg) for weight management launched in the U.S. in January 2026. Carries an FDA boxed warning for thyroid C-cell tumors; contraindicated with a personal/family history of medullary thyroid carcinoma or MEN 2. The U.S. semaglutide shortage was declared resolved in February 2025, ending most legal compounding. Semaglutide sold online as a 'research chemical,' or compounded using unapproved salt forms, is not an FDA-approved product.
Retatrutide
Investigational. NOT approved by the FDA, EMA, or any major regulator as of mid-2026; in Phase 3 (Lilly's TRIUMPH program), with a regulatory filing anticipated around late 2026 at the earliest. Per Lilly, legally available only to clinical-trial participants. No legal prescription or compounding pathway exists; anything sold online as 'retatrutide' is unapproved gray-market product.
Key differences
- Semaglutide is FDA-approved with years of Phase 3 data; retatrutide is investigational (Phase 3 ongoing) and legally available only in trials.
- Both weight-loss claims are graded S+, but semaglutide additionally has S+ cardiovascular-outcome evidence, while retatrutide's data is earlier-stage.
- Retatrutide hits three receptors to semaglutide's one and has shown larger trial weight loss — but without approval or long-term outcome data.
- 'Research' semaglutide and any online 'retatrutide' are gray-market and graded C.
The bottom line
Semaglutide is the established, approved drug with cardiovascular-outcome data behind it; retatrutide is the more dramatic early result you cannot legally get. We don't pick a winner — we show the grade behind each claim and the very different regulatory reality of the two.
PeptideIQ Base does not recommend, rank, or endorse any peptide, dose, or product. We grade the strength of the evidence so you can read it for yourself.
Read the full briefs
Full evidence brief
Semaglutide →
An FDA-approved GLP-1 medication (Ozempic, Wegovy, Rybelsus) with strong clinical-trial evidence for major weight loss and cardiovascular-risk reduction — but that evidence applies to the prescribed, regulated drug, not to the compounded or 'research-grade' semaglutide widely sold online.
Full evidence brief
Retatrutide →
An investigational Eli Lilly injectable that activates three gut/metabolic hormone receptors at once and has produced the largest weight loss yet seen in obesity trials — but is not approved or legally available outside clinical trials.
See every peptide, graded on one page
The Peptide Evidence Report Card grades all our peptides S+ to C on the strength of the human evidence. Research only — no hype, never a recommendation.
Get the report card →